成長ホルモン欠乏症(Growth Hormone Deficiency)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Growth Hormone Deficiency Overview 9
Therapeutics Development 10
Pipeline Products for Growth Hormone Deficiency – Overview 10
Pipeline Products for Growth Hormone Deficiency – Comparative Analysis 11
Growth Hormone Deficiency – Therapeutics under Development by Companies 12
Growth Hormone Deficiency – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Growth Hormone Deficiency – Products under Development by Companies 19
Growth Hormone Deficiency – Companies Involved in Therapeutics Development 21
Aeterna Zentaris Inc. 21
Aileron Therapeutics, Inc. 22
Ascendis Pharma A/S 23
Biogenomics Limited 24
Bolder Biotechnology, Inc. 25
Braasch Biotech LLC 26
CJ CheilJedang Corp. 27
Critical Pharmaceuticals Limited 28
Delpor, Inc. 29
Emisphere Technologies, Inc. 30
Flamel Technologies S.A. 31
Genexine, Inc. 32
HanAll Biopharma Co., Ltd. 33
Hanmi Pharmaceuticals, Co. Ltd. 34
Inbiopro Solutions Pvt. Ltd. 35
LG Life Sciences, Ltd. 36
OPKO Health, Inc. 37
Pfenex Inc. 38
Prometheon Pharma, LLC 39
Teva Pharmaceutical Industries Limited 40
Versartis, Inc. 41
XL-protein GmbH 42
Growth Hormone Deficiency – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ACP-001 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
albutropin – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ALRN-5281 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BBT-031 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CJ-40002 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CP-016 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GXH-9 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HL-032 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
HM-10560A – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IBPB-003HH – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
macimorelin acetate – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MOD-4023 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Pegylated Somatropin – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
somatropin – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
somatropin – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
somatropin – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
somatropin – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
somatropin biobetter – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
somatropin biobetter – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
somatropin biosimilar – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
somatropin biosimilar – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
somatropin pegol – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
somatropin SR – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
somatropin true patch – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SYN-20100504RU – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Vaccine for Growth Hormone Deficiencies – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
XL-020 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Growth Hormone Deficiency – Recent Pipeline Updates 87
Growth Hormone Deficiency – – Dormant Projects 100
Growth Hormone Deficiency – Discontinued Products 101
Growth Hormone Deficiency – Product Development Milestones 102
Featured News & Press Releases 102
Dec 29, 2014: Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study 102
Dec 15, 2014: Ascendis Pharma Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 102
Oct 30, 2014: Versartis Schedules Conference Call to Discuss Plans for Phase 3 Trial for VRS-317 in Pediatric Growth Hormone Deficiency Patients 103
Sep 18, 2014: Prometheon’s CEO/CSO Invited to Deliver Oral Presentation at the European Society for Paediatric Endocrinology Meeting 104
Sep 16, 2014: Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 104
Sep 11, 2014: Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference 105
Jun 30, 2014: Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317 105
Jun 27, 2014: OPKO Granted Patent from European Patent Office for Lagova 106
Jun 25, 2014: Strong Data from Lagova Phase II Clinical Study Presented during Webcast 106
Jun 23, 2014: OPKO Announces Positive Interim Six-Month Lagova (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110